Pacific Biosciences of California Inc. [NASDAQ: PACB] traded at a low on 07/01/21, posting a -1.74 loss after which it closed the day’ session at $34.36. The company report on June 24, 2021 that Pacific Biosciences and Rady Children’s Institute for Genomic Medicine Announce its First Research Collaboration for Whole Genome Sequencing.
HiFi Sequencing will be used on a cohort of rare disease cases with the aim to identify numerous variants, both small and structural, that are not readily detectable by short-read sequencing.
Pacific Biosciences of California, Inc. (Nasdaq: PACB)(“Pacific Biosciences” or “PacBio”), a leading provider of high-quality, long-read sequencing platforms, and Rady Children’s Institute for Genomic Medicine (RCIGM), a mission-driven, non-profit seeking to save lives and improve outcomes for patients, clinicians and families, shared that they are collaborating on a study which aims to identify potential disease-causing genetic variants and increase the solve rates of rare diseases.
The results of the trading session contributed to over 1788375 shares changing hands. Over the past one week, the price volatility of Pacific Biosciences of California Inc. stands at 5.57% while the volatility over the past one month is 5.31%.
The market cap for PACB stock reached $6.55 billion, with 194.79 million shares outstanding and 184.89 million shares in the current float. Compared to the average trading volume of 2.70M shares, PACB reached a trading volume of 1788375 in the most recent trading day, which is why market watchdogs consider the stock to be active.
What do top market gurus say about Pacific Biosciences of California Inc. [PACB]?
Based on careful and fact-backed analyses by Wall Street experts, the current consensus on the target price for PACB shares is $51.50 per share. Analysis on target price and performance of stocks is usually carefully studied by market experts, and the current Wall Street consensus on PACB stock is a recommendation set at 2.40. This rating represents a strong Buy recommendation, on the scale from 1 to 5, where 5 would mean strong sell, 4 represents Sell, 3 is Hold, and 2 indicates Buy.
Piper Sandler have made an estimate for Pacific Biosciences of California Inc. shares, keeping their opinion on the stock as Overweight, with their previous recommendation back on February 11, 2021. The new note on the price target was released on November 03, 2020, representing the official price target for Pacific Biosciences of California Inc. stock. Previously, the target price had yet another raise to $15, while JP Morgan analysts kept a Overweight rating on PACB stock.
The Average True Range (ATR) for Pacific Biosciences of California Inc. is set at 1.61, with the Price to Sales ratio for PACB stock in the period of the last 12 months amounting to 70.94. The Price to Book ratio for the last quarter was 23.86, with the Price to Cash per share for the same quarter was set at 6.09.
How has PACB stock performed recently?
Pacific Biosciences of California Inc. [PACB] gain into the green zone at the end of the last week, gaining into a positive trend and gaining by 5.79. With this latest performance, PACB shares gained by 28.50% in over the last four-week period, additionally plugging by 30.40% over the last 6 months – not to mention a rise of 853.12% in the past year of trading.
Overbought and oversold stocks can be easily traced with the Relative Strength Index (RSI), where an RSI result of over 70 would be overbought, and any rate below 30 would indicate oversold conditions. An RSI rate of 50 would represent a neutral market momentum. The current RSI for PACB stock in for the last two-week period is set at 66.59, with the RSI for the last a single of trading hit 68.51, and the three-weeks RSI is set at 62.63 for Pacific Biosciences of California Inc. [PACB]. The present Moving Average for the last 50 days of trading for this stock 28.29, while it was recorded at 34.90 for the last single week of trading, and 25.93 for the last 200 days.
Pacific Biosciences of California Inc. [PACB]: Deeper insight into the fundamentals
Operating Margin for any stock indicates how profitable investing would be, and Pacific Biosciences of California Inc. [PACB] shares currently have an operating margin of -132.31 and a Gross Margin at +41.28. Pacific Biosciences of California Inc.’s Net Margin is presently recorded at +37.27.
Return on Total Capital for PACB is now -42.25, given the latest momentum, and Return on Invested Capital for the company is 12.51. Return on Equity for this stock inclined to 15.06, with Return on Assets sitting at 10.46. When it comes to the capital structure of this company, Pacific Biosciences of California Inc. [PACB] has a Total Debt to Total Equity ratio set at 12.52. Additionally, PACB Total Debt to Total Capital is recorded at 11.13, with Total Debt to Total Assets ending up at 10.15. Long-Term Debt to Equity for the company is recorded at 11.23, with the Long-Term Debt to Total Capital now at 9.98.
Reflecting on the efficiency of the workforce at the company, Pacific Biosciences of California Inc. [PACB] managed to generate an average of $71,367 per employee. Receivables Turnover for the company is 4.91 with a Total Asset Turnover recorded at a value of 0.28.Pacific Biosciences of California Inc.’s liquidity data is similarly interesting compelling, with a Quick Ratio of 35.00 and a Current Ratio set at 35.40.
Earnings analysis for Pacific Biosciences of California Inc. [PACB]
The progress of the company may be observed through the prism of EPS growth rate, while Wall Street analysts are focusing on predicting the 5-year EPS growth rate for PACB. When it comes to the mentioned value, analysts are expecting to see the 5-year EPS growth rate for Pacific Biosciences of California Inc. go to -1.00%.
Insider trade positions for Pacific Biosciences of California Inc. [PACB]
There are presently around $5,780 million, or 85.30% of PACB stock, in the hands of institutional investors. The top three institutional holders of PACB stocks are: ARK INVESTMENT MANAGEMENT LLC with ownership of 21,301,191, which is approximately -25.271% of the company’s market cap and around 1.20% of the total institutional ownership; VANGUARD GROUP INC, holding 17,766,083 shares of the stock with an approximate value of $610.44 million in PACB stocks shares; and BLACKROCK INC., currently with $566.7 million in PACB stock with ownership of nearly 9.114% of the company’s market capitalization.
Positions in Pacific Biosciences of California Inc. stocks held by institutional investors increased at the end of August and at the time of the August reporting period, where 158 institutional holders increased their position in Pacific Biosciences of California Inc. [NASDAQ:PACB] by around 23,283,392 shares. Additionally, 106 investors decreased positions by around 28,882,191 shares, while 24 investors held positions by with 116,057,788 shares. The mentioned changes placed institutional holdings at 168,223,371 shares, according to the latest SEC report filing. PACB stock had 80 new institutional investments in for a total of 7,114,442 shares, while 28 institutional investors sold positions of 5,528,007 shares during the same period.